Durata Therapeutics to Present at Upcoming Investor Conferences

CHICAGO, May 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq: DRTX) announced today that Paul R. Edick, CEO, will be presenting an overview of the Company at two upcoming investor conferences.

• Bank of America Merrill Lynch Healthcare Conference: May 15 at 8:40am PDT, Las Vegas, Nevada
• UBS Global Healthcare Conference: May 19 at 2:00pm EDT, New York, New York

About Durata Therapeutics, Inc.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         [email protected]

         Media Relations Contact
         Geoff Curtis
         DJE Science
         (312) 233-1253
         [email protected]

Source: Durata Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GLOBAL CORD ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Global Cord Blood Corporation and Encourages Investors to Contact the Firm
• Bombardier Announces the Election of its Board of Directors
• ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC